Clinical Trials Browser

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

NCT06670976 2025-08-26

Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma

Phase 1 Withdrawn

Sarcoma

NCT05717140 2025-08-07

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Phase 1 Withdrawn

Dermatologic

Melanoma

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Phase 1/2 Withdrawn

GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

NCT05840770 2025-05-26

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Phase 2 Withdrawn

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06572631 2025-05-25

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05672095 2025-05-23

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Phase 1/2 Withdrawn

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06094842 2025-04-01

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Phase 1 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT06206876 2025-01-17

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT05653661 2025-01-07

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Withdrawn

Tumor-Agnostic

Neoplasm Metastasis

NCT06328036 2024-12-30

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Phase 2 Withdrawn

CNS

Glioblastoma

NCT06575725 2024-11-21

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05773664 2024-09-19

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

Phase 1 Withdrawn

CNS

Glioblastoma, Glioma

NCT05823480 2024-09-19

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06084845 2024-07-25

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Phase 2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05515692 2024-07-23

Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease

Phase EARLY_PHASE1 Withdrawn

OtherOther solid neoplasm

Hematopoietic and Lymphoid System Neoplasm

NCT06398587 2024-07-19

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT05411107 2024-05-17

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Phase 2 Withdrawn

Thoracic

Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

NCT06210750 2024-05-17

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06400264 2024-05-06

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Phase 2 Withdrawn

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05807126 2024-05-02

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Phase 1 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT06137651 2024-04-01

Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

Phase 1 Withdrawn

BreastCNS

Brain Neoplasms, Breast Neoplasms, Meningeal Carcinomatosis

NCT05967286 2024-03-20

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Phase 2 Withdrawn

Breast

Anatomic Stage III Breast Cancer AJCC v8

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04989283 2023-09-26

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05589844 2023-04-27

A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1 Withdrawn

Cytomegalovirus Infections